天宇股份：全资子公司药品坎地沙坦酯片获批准

Group 1 - The company Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Node Pharmaceutical Co., Ltd., has received the drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration [1] - Candesartan Cilexetil Tablets are indicated for primary hypertension, with a total R&D investment of approximately 11.4476 million yuan by Node Pharmaceutical and its subsidiaries [1] - The projected sales revenue for Candesartan Cilexetil Tablets in domestic sample hospitals and urban retail pharmacies is approximately 294 million yuan in 2024 [1]